REGISTER
China’s First Synthetic Liraglutide Approved
On 1 July 2026, the NMPA approved Hybio Pharmaceutical's liraglutide (H) injection, a Class 2.2 new drug, making it China's first chemically synthesized liraglutide. It is a GLP‑1 analogue for diabetes and weight management. Among five liraglutide generics approved in China, Hybio's is the first using a synthetic chemical route.

On 1 July, the official website of the National Medical Products Administration (NMPA) showed that Hybio Pharmaceutical Co., Ltd.’s Class 2.2 new drug liraglutide (H) injection had been approved for marketing. Hybio Pharmaceutical thus becomes the first company in China to produce liraglutide via a chemical synthesis route.

Liraglutide is a GLP‑1 analogue that exerts multiple physiological functions, including glucose‑dependent insulin secretion, protection of pancreatic β‑cells, and delayed gastric emptying to reduce appetite.

The originator product Victoza® (liraglutide, 6 mg) from Novo Nordisk was approved by the FDA in early 2010 for improving glycaemic control in patients with type 2 diabetes. Clinical trial results showed that liraglutide not only significantly improves glycaemic control, but also effectively reduces body weight and improves obesity‑related comorbidities. Based on these findings, Novo Nordisk developed the weight‑loss injection Saxenda® (liraglutide, 3 mg).

According to Novo Nordisk’s 2025 annual report, global sales of Victoza® reached DKK 3.020 billion (approximately RMB 3.27 billion), while global sales of Saxenda® totalled DKK 3.241 billion (approximately RMB 3.509 billion).

According to the PharmaCube PharmaGO database, a total of five liraglutide generic drugs have been approved for marketing in China; the other four are from The Federal Pharmaceutical Group, Huadong Medicine, Tonghua Dongbao, and Chia Tai Tianqing.

Just yesterday, Hybio Pharmaceutical announced another piece of good news: its other GLP‑1 product, tirzepatide, has been filed for marketing in the United States.

0
0
Loading